

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Telix Pharmaceuticals Limited
<b>ABN</b>	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Christian Behrenbruch
<b>Date of last notice</b>	2 June 2023

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct Interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	18 January 2024

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p>Direct Interest</p> <ul style="list-style-type: none"> <li>• 400,000 fully paid ordinary shares,</li> <li>• 200,000 share options with an exercise price of \$2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020 (TLX0006 - TLXAI).</li> <li>• 100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLX0009 - TLXAL).</li> <li>• 139,672 Share Appreciation Rights (TLX0012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.</li> <li>• 120,268 PSARs (TLX0015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023.</li> </ul> <p>Indirect interest</p> <ul style="list-style-type: none"> <li>• 22,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).</li> </ul>
<p><b>Class</b></p>	<p>Ordinary Shares</p>
<p><b>Number acquired</b></p>	<p>153,298</p>
<p><b>Number disposed</b></p>	<p>Nil</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Non-cash consideration. 200,000 share options (TLX0006 - TLXAI) were exercised via terms of a "cashless provision", whereby 46,702 options were forfeited in consideration of the exercise price payable of \$446,000. Estimated share valuation of the 153,298 acquired ordinary shares is \$1,686,278 (assuming \$11.00 share price as at 18 January 2024).</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p>Direct Interest</p> <ul style="list-style-type: none"> <li>• 553,298 fully paid ordinary shares,</li> <li>• 100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLXO009 - TLXAL).</li> <li>• 139,672 Share Appreciation Rights (TLXO012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.</li> <li>• 120,268 PSARs (TLXO015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023.</li> </ul> <p>Indirect interest</p> <ul style="list-style-type: none"> <li>• 22,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).</li> </ul>
<p><b>Nature of change</b></p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>153,298 ordinary shares acquired following the exercise of 200,000 options (TLXO006 - TLXAI) which were granted following shareholder approval at the AGM held 12 May 2020.</p>

**Part 2 – Change of director's interests in contracts – NOT APPLICABLE**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b></p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.